share_log

424B3: Prospectus

424B3: Prospectus

424B3:募资说明书
美股sec公告 ·  05/17 17:10
Moomoo AI 已提取核心信息
eFFECTOR Therapeutics, Inc., a biopharmaceutical company listed on the Nasdaq Capital Market under the symbols EFTR and EFTRW, filed a prospectus supplement on May 17, 2024. This filing updates and amends their previous prospectus dated April 2, 2024, and includes information from their Current Report on Form 8-K filed on the same day. The company's common stock and warrants closed at $1.98 and $0.02 respectively on May 16, 2024. eFFECTOR Therapeutics has been notified by Nasdaq that it has not met the Minimum Value of Listed Securities requirement of $35 million for the past thirty consecutive business days. The company has until November 12, 2024, to regain compliance with Nasdaq's continued listing requirements. Failure to do so may result in delisting. eFFECTOR Therapeutics is considering options to address the compliance issue but there is no guarantee of maintaining its listing.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company listed on the Nasdaq Capital Market under the symbols EFTR and EFTRW, filed a prospectus supplement on May 17, 2024. This filing updates and amends their previous prospectus dated April 2, 2024, and includes information from their Current Report on Form 8-K filed on the same day. The company's common stock and warrants closed at $1.98 and $0.02 respectively on May 16, 2024. eFFECTOR Therapeutics has been notified by Nasdaq that it has not met the Minimum Value of Listed Securities requirement of $35 million for the past thirty consecutive business days. The company has until November 12, 2024, to regain compliance with Nasdaq's continued listing requirements. Failure to do so may result in delisting. eFFECTOR Therapeutics is considering options to address the compliance issue but there is no guarantee of maintaining its listing.
Effector Therapeutics, Inc. 是一家在纳斯达克资本市场上市的生物制药公司,股票代码为EFTR和EFTRW,该公司于2024年5月17日提交了招股说明书补充文件。该文件更新并修订了他们先前于2024年4月2日提交的招股说明书,并包括他们当天提交的8-K表最新报告中的信息。该公司的普通股和认股权证于2024年5月16日分别收于1.98美元和0.02美元。纳斯达克已通知Effector Therapeutics,该公司在过去连续三十个工作日中未达到3500万美元的上市证券最低价值要求。该公司必须在2024年11月12日之前重新遵守纳斯达克的持续上市要求。不这样做可能会导致退市。Effector Therapeutics正在考虑解决合规问题的备选方案,但无法保证其继续上市。
Effector Therapeutics, Inc. 是一家在纳斯达克资本市场上市的生物制药公司,股票代码为EFTR和EFTRW,该公司于2024年5月17日提交了招股说明书补充文件。该文件更新并修订了他们先前于2024年4月2日提交的招股说明书,并包括他们当天提交的8-K表最新报告中的信息。该公司的普通股和认股权证于2024年5月16日分别收于1.98美元和0.02美元。纳斯达克已通知Effector Therapeutics,该公司在过去连续三十个工作日中未达到3500万美元的上市证券最低价值要求。该公司必须在2024年11月12日之前重新遵守纳斯达克的持续上市要求。不这样做可能会导致退市。Effector Therapeutics正在考虑解决合规问题的备选方案,但无法保证其继续上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息